These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 12198592

  • 1. [Management of patients with Type 2B von Willebrand's disease during delivery and puerperium].
    Güth U, Tsakiris DA, Reber A, Holzgreve W, Hösli I.
    Z Geburtshilfe Neonatol; 2002; 206(4):151-5. PubMed ID: 12198592
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G.
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, Inbal A.
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [Abstract] [Full Text] [Related]

  • 4. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 5. [Pre- and postpartum hemostasis in type II Willebrand-Jürgens syndrome].
    Lutze G, Canzler E, Franke D, Töpfer G.
    Z Gesamte Inn Med; 1989 Feb 15; 44(4):117-20. PubMed ID: 2785733
    [Abstract] [Full Text] [Related]

  • 6. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ, van Vliet HH, Berneman Z, Schroyens W, Gadisseur A.
    Acta Haematol; 2009 Feb 15; 121(2-3):167-76. PubMed ID: 19506363
    [Abstract] [Full Text] [Related]

  • 7. Pregnancy in type 2B VWD: a case series.
    Ranger A, Manning RA, Lyall H, Laffan MA, Millar CM.
    Haemophilia; 2012 May 15; 18(3):406-12. PubMed ID: 22077376
    [Abstract] [Full Text] [Related]

  • 8. [Willebrand's disease and pregnancy. Fifteen cases].
    Depret-Mosser S, Marey A, Parquet-Gernez A, Theeten G, Goudemand J, Codaccioni X, Vinatier D, Monnier JC.
    J Gynecol Obstet Biol Reprod (Paris); 1996 May 15; 25(4):405-10. PubMed ID: 8815140
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, Street A, Maher D, Barrese G, Stone C, Lloyd J.
    Haemophilia; 2010 Jul 01; 16(4):615-24. PubMed ID: 20331755
    [Abstract] [Full Text] [Related]

  • 12. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S, Mezzasoma AM, Leone M, Gresele P.
    Haematologica; 2007 Dec 01; 92(12):1647-54. PubMed ID: 18055988
    [Abstract] [Full Text] [Related]

  • 13. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
    Castaman G, Federici AB, Rodeghiero F, Mannucci PM.
    Haematologica; 2003 Jan 01; 88(1):94-108. PubMed ID: 12551832
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Clin Appl Thromb Hemost; 2006 Oct 01; 12(4):397-420. PubMed ID: 17000885
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.
    Semin Thromb Hemost; 2006 Sep 01; 32(6):636-45. PubMed ID: 16977574
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ.
    Thromb Haemost; 2007 Jun 01; 97(6):922-30. PubMed ID: 17549293
    [Abstract] [Full Text] [Related]

  • 19. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.
    Acta Haematol; 2009 Jun 01; 121(2-3):71-84. PubMed ID: 19506352
    [Abstract] [Full Text] [Related]

  • 20. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Clin Appl Thromb Hemost; 2006 Jul 01; 12(3):277-95. PubMed ID: 16959681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.